926265-87-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-oxo-2-pyrrolidin-1-ylethyl)aniline is used as an intermediate in the synthesis of various pharmaceuticals for its anesthetic and analgesic properties. It has been studied for its potential use in the treatment of pain and inflammation.
Used in Dye Industry:
4-(2-oxo-2-pyrrolidin-1-ylethyl)aniline is used as an intermediate in the synthesis of various dyes due to its chemical structure and properties.
Used in Antifungal Applications:
4-(2-oxo-2-pyrrolidin-1-ylethyl)aniline is used as a potential candidate for the development of new antifungal drugs due to its antifungal activity.
It is important to handle and use this chemical with care, as it may pose hazards to human health and the environment.

InChI:InChI=1/C12H16N2O/c13-11-5-3-10(4-6-11)9-12(15)14-7-1-2-8-14/h3-6H,1-2,7-9,13H2

Upstream product

• 555-16-8 4-nitrobenzaldehdye 
• 51738-10-4 2,2-dibromo-1-(4-nitrophenyl)ethene 
• 168897-62-9 2-(4-nitrophenyl)-1-(pyrrolidin-1-yl)ethan-1-one 

Downstream Products

• 168897-20-9 4-(2-pyrrolidin-1-yl-ethyl)phenylamine 

Relevant academic research and scientific papers

Synthesis and biological evaluation of new 4β-anilino-4′-O- demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

A series of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4β position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route.

Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors

Compounds of formula (I): wherein Ra, Rb, R, X1 and X2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.